Larry Zeitlin, Robert W Cross, Courtney Woolsey, Brandyn R West, Viktoriya Borisevich, Krystle N Agans, Abhishek N Prasad, Daniel J Deer, Lauren Stuart, Maria McCavitt-Malvido, Do H Kim, James Pettitt, James E Crowe, Kevin J Whaley, David Veesler, Antony Dimitrov, Dafna M Abelson, Thomas W Geisbert, Christopher C Broder
No licensed vaccines or therapies exist for patients infected with Nipah virus (NiV), although an experimental human monoclonal antibody (mAb) cross-reactive to the NiV and Hendra virus (HeV) G glycoprotein, m102.4, has been tested in a phase 1 trial and has been provided under compassionate use for both HeV and NiV exposures. NiV is a highly pathogenic zoonotic paramyxovirus causing regular outbreaks in humans and animals in South and Southeast Asia. The mortality rate of NiV infection in humans ranges from 40% to more than 90%, making it a substantial public health concern...
April 3, 2024: Science Translational Medicine